| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10120-016-0614-4 |
| P698 | PubMed publication ID | 27189323 |
| P2093 | author name string | Mizutomo Azuma | |
| Satoshi Tanabe | |||
| Wasaburo Koizumi | |||
| Keisho Chin | |||
| Satoshi Matsusaka | |||
| Yosuke Kumekawa | |||
| Norisuke Nakayama | |||
| Ken Nishimura | |||
| Kenji Ishido | |||
| Yasuhiro Inokuchi | |||
| P2860 | cites work | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma | Q33392300 | ||
| Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors | Q33822801 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. | Q35051856 | ||
| A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). | Q35120795 | ||
| Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer | Q35754251 | ||
| Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer | Q36612612 | ||
| Phase II study of S-1 in patients with advanced biliary tract cancer | Q36696249 | ||
| A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer | Q40498631 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. | Q45152936 | ||
| An early phase II study of S-1 in patients with metastatic pancreatic cancer | Q46592427 | ||
| Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | Q46828997 | ||
| Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators | Q71665880 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 350-357 | |
| P577 | publication date | 2016-05-17 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. | |
| P478 | volume | 20 |
| Q33748302 | Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. |
| Q45384459 | Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial |
| Q57035043 | Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer |
Search more.